Trial results regarding the use of Penguin Cold Caps for hair loss prevention in breast cancer patients undergoing chemotherapy were posted on 2026-04-28. The study, which enrolled 12 participants, aimed to estimate the efficacy of these caps in reducing chemotherapy-induced alopecia.
Background
Chemotherapy-induced alopecia (CIA) is a common and distressing side effect for many cancer patients, particularly those undergoing treatment for breast cancer. While not life-threatening, hair loss can significantly impact a patient's quality of life, body image, and psychological well-being during an already challenging period. Cold cap therapy, such as the Penguin Cold Caps, works by constricting blood vessels in the scalp, reducing the amount of chemotherapy drugs that reach hair follicles and thereby potentially mitigating hair loss.
Trial design
This completed trial (NCT03289364) enrolled 12 participants with Breast Cancer. The study's objective was to estimate the efficacy of Penguin cold caps in preventing or reducing hair loss in patients receiving (neo)adjuvant chemotherapy, using one of four common regimens for early-stage breast cancer. The trial did not specify a phase.
Key results
The trial measured the efficacy of Penguin Cold Caps for the prevention or reduction of chemotherapy-induced alopecia. The results indicated that 4 participants, 3 participants, and 3 participants were counted for efficacy in three separate measurements.
Additional measurements included exit interviews. For the 'Was It Worth It?' questionnaire, participant counts were recorded as 9, 10, 8, 5, and 5 participants.
The EORTC QLQ-C30 Exit Interview, a quality of life assessment, yielded mean scores for the Penguin Cold Caps group: 64.58 (Standard Deviation 19.8), 84.17 (Standard Deviation 16.3), 62 (Standard Deviation 21.7), and 69.79 (Standard Deviation 24.8) on a scale.
What this means
The results from this small trial of 12 participants provide initial data on the use of Penguin Cold Caps for preventing or reducing hair loss in breast cancer patients undergoing chemotherapy. The recorded counts for efficacy suggest varying degrees of success among participants. The exit interview data and quality of life scores offer insights into participant experience and perceived value, which are important considerations for patient care. Given the small sample size and the nature of the reported measurements, these findings contribute to the understanding of cold cap use but do not provide definitive conclusions on widespread efficacy.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03289364, titled 'Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients,' were posted on 2026-04-28 on clinicaltrials.gov.